Ibrutinib

Routes
Oral (PO)
Half-Life (t½)
PO: 5h
Formula
C25H24N6O2
Molecular Weight
440.5 g/mol
PubChem CID
24821094
Aliases
Imbruvica, PCI-32765

Pharmacological Mechanism

First-in-class covalent BTK (Bruton tyrosine kinase) inhibitor — irreversible Michael acceptor that binds Cys481 in the BTK ATP pocket. Indications: CLL/SLL, mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, cGVHD. Strong CYP3A4 substrate (F ~3%; raising it to ~10% with mild inducers, contraindicated with strong inhibitors due to risk of atrial fibrillation + bleeding). Off-target effects on EGFR, ITK, TEC, HER2 account for the rash + diarrhea + AF profile. PK (Imbruvica label, SS 560 mg PO qd): AUC 953 ± 705 ng·h/mL, t½ 4-6 h, Tmax 1-2 h, absolute F 2.9% fasted (doubles to ~6% with food — administration with food recommended). Apparent V/F ~4200 L; true Vd ~122 L. CYP3A4 substrate; massive food effect + strong inducer/inhibitor sensitivity.

Half-Life & Elimination Curve (PO: 5h)

100%50%25%12.5%0%0h0×t½5h1×t½10h2×t½15h3×t½20h4×t½25h5×t½0×t½ (0h): 100% remaining (~69.1 µg/L)1×t½ (5h): 50% remaining (~34.6 µg/L)2×t½ (10h): 25% remaining (~17.3 µg/L)3×t½ (15h): 12.5% remaining (~8.64 µg/L)4×t½ (20h): 6.3% remaining (~4.32 µg/L)5×t½ (25h): 3.1% remaining (~2.16 µg/L)
Plasma (PO)t½ Decay (5h)
  • 0×t½0h100% (69.1 µg/L)
  • 1×t½5h50% (34.6 µg/L)
  • 2×t½10h25% (17.3 µg/L)
  • 3×t½15h12.5% (8.64 µg/L)
  • 4×t½20h6.3% (4.32 µg/L)
  • 5×t½25h3.1% (2.16 µg/L)
Elimination t½5h (PO)
Rate Constant (ke)0.139 h⁻¹
Time to Peak (Tmax)2.65h
Est. Peak (Cmax)69.1 µg/L
Clearance (CL)16.9 L/h
97% Washout (5×t½)25h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers